World Leader in Regenerative Medicine to Be Among Companies Attending Noble Financial BIOX Investor Conference

STAMFORD, CT, Aug 28 (Marketwire) --
Noble Financial Capital Markets (Noble) announced today that Australian
company, Mesoblast (ASX: MSB) (PINKSHEETS: MBLTY) will be among the 30
life sciences companies to attend BIOX, an investor exposition to be held
at the University of Connecticut in Stamford, CT on September 24-25,
2012. Australia is a leading location for biotechnology companies in Asia
Pacific with 470 core biotechnology companies; 49 percent are in human
therapeutics. The country has a well-established medical device industry,
a strong position in nano-biotechnology, and is internationally regarded
for its expertise in stem cell research. With market capitalization of
close to $2 billion USD, Mesoblast is the world's leading developer of
innovative biological products for the broad field of regenerative
medicine. The company's commercial strategy is based on its unique
proprietary adult mesenchymal precursor cells.

Stem cell therapy companies are now beginning to emerge with novel
mechanisms to fight any given number of indications. Stem cell technology
is extremely time and money intensive. Leaders in the space demonstrate
varying levels of success, different approaches of creating and applying
the stem cell therapies, and varied levels of partnership and investor
contributions. Understanding what differentiates one from another and how
to rank and evaluate each company's potential is an ongoing investor
challenge. While failures are costly, successes lead to FDA approvals,
huge marketability with little competition, and profitable licensing
deals or acquisition by large Pharma.

"A good example of stem cell validation is the strategic alliance of
Mesoblast and Teva Pharmaceuticals," said Nathan Cali, Noble's Senior
Research Analyst. "The fact that a large pharmaceutical company like Teva
is funding all late-stage clinical development and the sales and
marketing costs for product commercialization of Mesoblast's novel adult
stem cell therapies [for degenerative conditions of the cardiovascular
and central nervous systems], speaks volumes as to the advancements in
cell therapy," he said. "At BIOX investors will have access to a cross
section of some of the most important players in the space -- exciting
stuff," he added.

In addition to Mesoblast, companies involved in cell therapy that are
expected to attend are: Athersys (ATHX), Cytori (CYTX), Cytomedix (CMXI),
ISTO Technologies (Private Company), Pluristem (PSTI), Prima Biomed
(PBMD) and Neostem (NBS).

Two, one-hour panels will be devoted to regenerative medicine with world
renowned opinion leaders Dr. Charles Vacanti (Harvard Medical School) and
Dr. Mark Noble (University of Rochester) joining select corporate
executives to discuss and debate the latest scientific advancements.
Additionally, two panels will cover some of today's most relevant life
sciences topics including immunotherapy and targeted oncology. Organized
breakout sessions, scheduled one-on-one meeting between executives and
investors, and an evening networking function rounds-out the agenda.

Investor participation is by invitation only.

Conference website: http://www.nobleresearch.com/BioExposition.htm

Contact
Mark Pinvidic
mpinvidic@noblefcm.com

Copyright 2012, Marketwire, All rights reserved.

-0-